{"id":"NCT00687219","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Efficacy and Safety of Peginterferon Alfa-2b and Ribavirin Therapy in Subjects With Type C Compensated Liver Cirrhosis (Study P05116)","officialTitle":"Treatment of Patients With Compensated Liver Cirrhosis With SCH 54031 + Ribavirin","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-06","primaryCompletion":"2010-10","completion":"2010-10","firstPosted":"2008-05-30","resultsPosted":"2011-12-02","lastUpdate":"2017-04-07"},"enrollment":102,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hepatitis C, Chronic","Liver Cirrhosis"],"interventions":[{"type":"BIOLOGICAL","name":"Peginterferon alfa-2b","otherNames":["SCH 054031"]},{"type":"DRUG","name":"Ribavirin","otherNames":["SCH 018908"]}],"arms":[{"label":"Peginterferon alfa-2b + Ribavirin","type":"EXPERIMENTAL"}],"summary":"The objective is to evaluate the efficacy and safety of combination therapy with peginterferon alfa-2b 1.0 Âµg/kg/week subcutaneous (SC) + ribavirin administered for 48 weeks in participants with chronic hepatitis C and type C compensated liver cirrhosis. Participants who are hepatitis C virus ribonucleic acid (HCV-RNA) positive after 24 weeks of treatment will be discontinued from therapy.","primaryOutcome":{"measure":"Number of Participants With Undetectable HCV-RNA at Week 72 (Sustained Virologic Response)","timeFrame":"Measured at 24 weeks after 48 weeks treatment (72 weeks)","effectByArm":[{"arm":"Peginterferon Alfa-2b + Ribavirin","deltaMin":41,"sd":null}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":10,"exclusionCount":13},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":14,"n":102},"commonTop":["PYREXIA","WHITE BLOOD CELL COUNT DECREASED","HAEMOGLOBIN DECREASED","MALAISE","LYMPHOCYTE COUNT DECREASED"]}}